LindaLouiseNeumanMDMBA

Healthcare Research and Healthcare Policy

Chief Medical Officer Aeglea BioTherapeutics

Dr. Neuman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Ascension St Vincent Hospital IndianapolisResidency, Internal Medicine, 1992 - 1994
Southern Illinois UniversityResidency, Internal Medicine, 1991 - 1992
Indiana University School of Medicine/Methodist HospitalInternship, Transitional Year, 1990 - 1991
Southern Illinois University School of MedicineClass of 1990

Abstracts/Posters

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice
Linda Neuman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable As Assessed By the Thrombin Generation Test in Hemophili...
Linda Neuman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic AlternativesApril 12th, 2023
Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical OfficerNovember 15th, 2022
Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology ConferenceDecember 7th, 2020
Join now to see all